Beacon Pharmaceuticals PLC

BEACONPHAR

BD0482BECON5

Pharmaceuticals

End-of-day quote Dhaka S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
189.9 ^BDT	-2.96%		-5.57%	-22.49%

Feb. 13	Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
Jan. 30	Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary	CI

Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2021

November 29, 2021 at 10:12 am EST

The Board of Directors of Beacon Pharmaceuticals Ltd. has recommended 15% cash dividend for the year ended on June 30, 2021.

Latest news about Beacon Pharmaceuticals PLC

Beacon Pharmaceuticals PLC Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 12	CI
Beacon Pharmaceuticals plc Announces Appointment of Md. Sahabuddin FCS as Company Secretary	Jan. 30	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the First Quarter Ended September 30, 2023	Jan. 23	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Full Year Ended June 30, 2023	Dec. 05	CI
Beacon Pharmaceuticals plc Recommends Cash Dividend for the Year Ended June 30, 2023	23-10-23	CI
Beacon Pharmaceuticals plc Appoints Mr. Ulfat Karim as the Director and Chief Operating Officer	23-08-13	CI
Beacon Pharmaceuticals PLC Announces Appointment of Jalal Uddin as Chief Financial Officer	23-06-19	CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as CFO	23-05-11	CI
Beacon Pharmaceuticals plc Announces Resignation of Abdul Haque Sarder as Director (Finance & Accounts)	23-05-11	CI
Beacon Pharmaceuticals PLC Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	23-05-03	CI
Beacon Pharmaceuticals Limited will Change its Name to Beacon Pharmaceuticals PLC	23-04-16	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	23-02-13	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2022	22-11-22	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2022	22-11-22	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2022	22-10-26	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	22-05-18	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	22-02-10	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended September 30, 2021	21-12-27	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended June 30, 2021	21-12-20	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2021	21-11-29	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter Ended March 31, 2021	21-06-05	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended December 31, 2020	21-02-04	CI
Beacon Pharmaceuticals Ltd. Recommends Cash Dividend for the Year Ended on June 30, 2020	20-10-28	CI
Beacon Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter Ended March 31, 2020	20-07-22	CI
Exclusive: Bangladesh's Beximco to begin producing COVID-19 drug remdesivir-COO	20-05-05	RE

Chart Beacon Pharmaceuticals PLC

Duration

Period

More charts

Beacon Pharmaceuticals PLC, formerly Beacon Pharmaceuticals Limited, is a Bangladesh-based pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical finished formulation products and lifesaving Intravenous (I.V) fluids, active pharmaceuticals ingredients, biotech products and genetic engineering products which it sells in the local markets as well as the international markets. The Company also provides contract manufacturing and tool manufacturing services. Its products are focused on various drugs, such as anticancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxant, antihistamine, analgesics and non-steroidal anti-inflammatory drugs (NSAIDS), among others. The Company's product categories include general, oncology, anti-viral and biotech. Its products include Favipiravir, Remdisivir INN, Meropenem, Bendamustine, Bleomycin Sulfate, Daunorubicin, Gemcitabine, Darbepoetin alfa and Filgrastim.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BEACON PHARMACEUTICALS PLC	-22.49%	400M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B